Targeted therapy: Leveraging ADCC to enhance anti-HER2 therapy
- PMID: 28195234
- DOI: 10.1038/nrclinonc.2017.19
Targeted therapy: Leveraging ADCC to enhance anti-HER2 therapy
Comment on
-
First-in-human phase 1 study of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody, in patients with HER2-positive advanced solid tumors.Ann Oncol. 2017 Apr 1;28(4):855-861. doi: 10.1093/annonc/mdx002. Ann Oncol. 2017. PMID: 28119295 Free PMC article. Clinical Trial.
References
-
- Ann Oncol. 2017 Jan 24;:null - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous
